Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria

The Journal of Infectious Diseases
T NomuraT E Wellems

Abstract

Chloroquine (CQ)-resistant Plasmodium vivax malaria was first reported 12 years ago, nearly 30 years after the recognition of CQ-resistant P. falciparum. Loss of CQ efficacy now poses a severe problem for the prevention and treatment of both diseases. Mutations in a digestive vacuole protein encoded by a 13-exon gene, pfcrt, were shown recently to have a central role in the CQ resistance (CQR) of P. falciparum. Whether mutations in pfcrt orthologues of other Plasmodium species are involved in CQR remains an open question. This report describes pfcrt homologues from P. vivax, P. knowlesi, P. berghei, and Dictyostelium discoideum. Synteny between the P. falciparum and P. vivax genes is demonstrated. However, a survey of patient isolates and monkey-adapted lines has shown no association between in vivo CQR and codon mutations in the P. vivax gene. This is evidence that the molecular events underlying P. vivax CQR differ from those in P. falciparum.

Citations

Apr 14, 2005·International Journal for Parasitology·P M Jones, A M George
Apr 22, 2004·Trends in Parasitology·Jetsumon SattabongkotLiwang Cui
Jul 21, 2004·Transactions of the Royal Society of Tropical Medicine and Hygiene·Y HamediS Looareesuwan
Aug 30, 2003·Molecular and Biochemical Parasitology·Gregory S NolandDavid J Sullivan
Mar 7, 2002·Microbes and Infection·John E Hyde
May 24, 2003·Trends in Parasitology·Jane Carlton
Dec 15, 2010·Biochemistry·Paul D Roepe
Sep 24, 2008·The Journal of Infectious Diseases·R SuwanaruskR N Price
Nov 17, 2011·The Journal of Antimicrobial Chemotherapy·Khadijetou Mint LekweirySébastien Briolant
Sep 24, 2008·Antimicrobial Agents and Chemotherapy·Céline BarnadasDidier Ménard
Sep 30, 2010·Antimicrobial Agents and Chemotherapy·R N PriceB Russell
Dec 25, 2002·Antimicrobial Agents and Chemotherapy·Pharath LimThierry Fandeur
Oct 27, 2004·Antimicrobial Agents and Chemotherapy·J Kevin Baird
Jul 15, 2009·Clinical Microbiology Reviews·J Kevin Baird
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Ravit Arav-Boger, Theresa A Shapiro
Sep 5, 2009·The Journal of Clinical Investigation·Thomas E WellemsRick M Fairhurst
Sep 16, 2011·BMC Evolutionary Biology·Kate B GardnerCharles J Woodrow
Dec 16, 2010·Future Microbiology·Ingrid B Müller, John E Hyde
Jul 31, 2007·Future Microbiology·Claire Kidgell, Elizabeth A Winzeler
Aug 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Michele D Hastings, Carol Hopkins Sibley
Feb 16, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Purva GuptaVineeta Singh
Jul 19, 2005·Expert Opinion on Investigational Drugs·Dharmendar RathoreSanjai Kumar
Feb 19, 2016·Malaria Journal·Larissa Rodrigues GomesMaria de Fatima Ferreira-da-Cruz
May 3, 2011·FEBS Letters·Ines PetersenMichael Lanzer
Jan 18, 2005·The American Journal of the Medical Sciences·Aurora E VicasCarlos del Rio
Mar 22, 2016·Tropical Parasitology·Hiasindh Ashmi Antony, Subhash Chandra Parija
Oct 10, 2012·Trends in Parasitology·Ric N PriceQin Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.